Lord, Abbett & Co
CNTA

Lord, Abbett & Co’s Centessa Pharmaceuticals CNTA Stock Holding History

Lord, Abbett & Co’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-446,196
Closed -$6.42M – 526
2025
Q1 		$6.42M Buy
446,196
+5,701
+1% +$93.3K 0.02% 434
2024
Q4 		$7.38M Buy
440,495
+171,290
+64% +$2.84M 0.02% 425
2024
Q3 		$4.3M Buy
+269,205
New +$3.3M 0.01% 486

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lord, Abbett & Co's CNTA Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 446,196 shares — an estimated $6.42M sold.

Lord, Abbett & Co first reported a position in CNTA in Q3 2024 and held it in 3 quarters. The position peaked at $7.38M in Q4 2024. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Lord, Abbett & Co reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 446,196 Centessa Pharmaceuticals shares in Q2 2025, an estimated $6.42M.
  • Lord, Abbett & Co first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Lord, Abbett & Co's Centessa Pharmaceuticals position peaked at $7.38M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.